Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 115Lenalidomide 74daratumumab 57Bortezomib 52carfilzomib 41Calcium Dobesilate 36pomalidomide 35Cyclophosphamide 26isatuximab 23belantamab mafodotin 22Specimen Handling 20Biopsy 20Magnetic Resonance Spectroscopy 17dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 12ixazomib 11iberdomide 11fludarabine 11elotuzumab 11selinexor 10Melphalan 10fludarabine phosphate 8talquetamab 7X-Rays 7trametinib 6nirogacestat 6venetoclax 5Thalidomide 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Multiple Myeloma × incomplete Freund's adjuvant × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡